Rituximab treatment in lupus nephritis--where do we stand?

Rituximab treatment in lupus nephritis--where do we stand?

Item
http://www.wikidata.org/entity/Q38095863
Pathogenesis of renal disease in systemic lupus erythematosus--the role of autoantibodies and lymphocytes subset abnormalitiesLupus nephritis: glycogen synthase kinase 3β promotion of renal damage through activation of the NLRP3 inflammasome in lupus-prone mice.Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus.Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to EculizumabRecent clinical trials in lupus nephritis.Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritisRituximab and lupus--a promising pair?Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.Systemic lupus erythematosus.
P2860

Rituximab treatment in lupus nephritis--where do we stand?

Item
http://www.wikidata.org/entity/Q38095863
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Rituximab treatment in lupus nephritis--where do we stand?
@en
type
label
Rituximab treatment in lupus nephritis--where do we stand?
@en
prefLabel
Rituximab treatment in lupus nephritis--where do we stand?
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Rituximab treatment in lupus nephritis--where do we stand?
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P698